A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

To join this study, you must be an adult with newly diagnosed non-small cell lung cancer that your doctors believe can be fully removed by surgery. Your cancer should be at a specific stage (Stage II to IIIB, N2). We will also need to check some things about your cancer, like if a specific marker called PD-L1 is present, and make sure the cancer hasn't spread to distant parts of your body.

You also need to be generally in good health, with your body – including your blood, liver, and kidneys – working well. You shouldn't have had any other cancer treatments recently, nor should you have certain conditions like uncontrolled HIV or hepatitis, or a known heart problem called myocarditis. We'll also check for specific genetic changes in your tumour that are sometimes treated differently.

If you join this study, you will receive a combination of medicines (either Fianlimab, Cemiplimab, and chemotherapy, or Cemiplimab and chemotherapy) before and after your surgery. These medicines are given through an IV (a drip into your vein). You will have regular visits to the clinic for these treatments and to have check-ups. These check-ups will include blood tests, scans, and physical examinations to see how you are doing, how the treatment is working, and to monitor for any side effects. Researchers will also collect information on your quality of life. The total duration of your participation in the study, including follow-up after treatment, will be discussed in detail by your medical team.